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Abstract
Background: Vaccination of poultry to control highly pathogenic avian influenza virus (HPAIV) H5N1 is used in several
countries. HPAIV H5N1 of clade 2.2.1 which is endemic in Egypt has diversified into two genetic clades. Clade 2.2.1.1
represents antigenic drift variants in vaccinated commercial poultry while clade 2.2.1.2 variants are detected in humans
and backyard poultry. Little is known about H5N1 infection in vaccinated turkeys under field conditions.
Case presentation: Here, we describe an HPAI H5N1 outbreak in a vaccinated meat-turkey flock in Egypt. Birds were
vaccinated with inactivated H5N2 and H5N1 vaccines at 8 and 34 days of age, respectively. At 72nd day of age (38 days
post last vaccination), turkeys exhibited mild respiratory signs, cyanosis of snood and severe congestion of the internal
organs. Survivors had a reduction in feed consumption and body gain. A mortality of ~29% cumulated within 10 days
after the onset of clinical signs. Laboratory diagnosis using RT-qPCRs revealed presence of H5N1 but was negative for
H7 and H9 subtypes. A substantial antigenic drift against different serum samples from clade 2.2.1.1 and clade 2.3.4.4
was observed. Based on full genome sequence analysis the virus belonged to clade 2.2.1.2 but clustered with recent
H5N1 viruses from 2015 in poultry in Israel, Gaza and Egypt in a novel subclade designated here 2.2.1.2a which is
distinct from 2014/2015 2.2.1.2 viruses. These viruses possess 2.2.1.2 clade-specific genetic signatures and also mutations in
the HA similar to those in clade 2.2.1.1 that enabled evasion from humoral immune response. Taken together, this
manuscript describes a recent HPAI H5N1 outbreak in vaccinated meat-turkeys in Egypt after infection with a virus
representing novel distinct 2.2.1.2a subclade.
Conclusions: Infection with HPAIV H5N1 in commercial turkeys resulted in significant morbidity and mortality despite of
vaccination using H5 vaccines. The isolated virus showed antigenic drift and clustered in a novel cluster designated here
2.2.1.2a related to viruses in poultry in Israel, Gaza and Egypt. Enforcement of biosecurity and constant update of vaccine
virus strains may be helpful to protect vaccinated birds and prevent spillover infection to neighbouring countries.
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Background
Findings
Avian influenza (AI) viruses are members of the genus
influenza virus A in the family Orthomyxoviridae and
possess a single-stranded RNA genome composed of
eight gene segments encode at least ten viral proteins [1].
The two envelope glycoproteins hemagglutinin (HA) and
neuraminidase (NA) are responsible for virus attachment
to and release from the host cell, respectively. HA is the
main determinant of virulence and immunogenicity. The
polymerase basic (PB) 1 and 2, polymerase acidic (PA)
and nucleoprotein (NP) represent the minimal replicative
unit of the virus. In addition, the bicistronic matrix (M)
and non-structural (NS) gene segments each encode two
proteins: M1 and M2, and NS1 and nuclear export protein
(NEP), respectively. Some AI viruses possess PA-x and
PB1-F2 proteins encoded by a frameshift of PA and PB1
gene segments. All proteins are associated with the virion
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except the nonstructural NS1 and PB1-F2 [1]. To date, 16
HA (H1-16) and 9 NA (N1–N9) subtypes have been de-
tected in wild birds, the natural reservoir of the virus.
Transmission of AI viruses from wild birds to domestic
poultry resulted in severe losses in the poultry industry
and endangered human health. In contrast to the low
pathogenic (LP) nature of AI in wild birds, in domestic
poultry H5 and H7 viruses may shift to high pathogenic
(HP) forms after the acquisition of point mutations or
swapping of gene segments between different AI subtypes
[2]. In 1996/1997, an HPAI H5N1 virus was generated by
the reassortment of the HA and NA segments of H5N1
with internal segments from H6N1 or H9N2 viruses in
live bird markets in Hong Kong [3]. Since then, the virus
has evolved into 10 different phylogenetic clades (desig-
nated clade 0 to 9) and tens of subclades according to the
diversity of the HA gene [4].
Turkeys play an important role in the adaptation of wild-
bird viruses to gallinaceous poultry. They also act as mixing
vessel for the generation of reassortant viruses sharing sig-
natures of human, avian and swine influenza viruses [5–8].
The susceptibility of turkeys to LP and HP AI viruses is
higher than that of chickens and waterfowl [9, 10]. Severe
mortality has been reported in natural outbreaks due to in-
fection with HPAIV H7N1 [9], and recently with H5N2
and H5N8 in North America [11, 12] and Germany [13].
Therefore, vaccination of turkeys with a variety of H5 virus
vaccines was implemented in the field to protect turkeys
from lethal infection by HPAIV. The frequency and time of
vaccination as well as the dose of the inactivated vaccine in
turkeys are mostly different from these of chickens [14].
Antigenic-drift variants represented a serious challenge for
the efficacy of current vaccines in poultry. Field reports on
vaccinal breaks in chicken flocks are common [15–19],
whereas little is known about H5N1 in turkeys [20].
Egypt is one of the few countries with an endemic
status of clade 2.2.1 HPAI H5N1 virus, which diversi-
fied into two distinct subclades designated 2.2.1.1 and
2.2.1.2. Viruses in clade 2.2.1.1 circulated in vacci-
nated poultry, including turkeys, from 2007 to 2014
despite intensive blanket vaccination using over 20
diverse H5 vaccines [21–23]. Meanwhile, clade 2.2.1.2
viruses were observed mainly in backyard birds and
humans, and recently in the commercial birds. They
caused severe socioeconomic losses in the poultry indus-
try and posed a serious pandemic threat because of their
affinity to human-type receptors [24, 25]. The emergence
of antigenic-drift variants, improper vaccination, and or
immunosuppression are commonly held responsible for
vaccination failure mainly in chickens. However, no
detailed data are available on turkeys [21].
In this manuscript, we described a recent outbreak
with HPAI H5N1 in a vaccinated meat turkey flock at
10 weeks of age. The flock was vaccinated twice with
H5 vaccines at 8 and 34 day of age. Details on feed con-
sumption, body weight and mortality are provided. Full
genome characterization of the isolated virus in relation to
the vaccine and circulating viruses were analyzed.
Case Presentation
Clinical examination
Data on the feed consumption and mean body weight per
week was calculated for living birds and summarized in
Fig. 1. Generally, the feed consumption was normal and in-
creased with time. Likewise, birds had a steady increase in
body weight. At weeks 10 to 12 a remarkable decrease in
feed consumption and body weight was observed (Fig. 1a),
when birds started exhibiting clinical signs of mild respira-
tory distress, sneezing and coughing accompanied with
sudden onset of mortalities. High mortality started at week
10 and increased in weeks 11 and 12 then decreased at
weeks 13 and 14, where 33, 288, 362, 74 and 34 birds died,
respectively. A second shorter increase of mortality at week
16 was observed (Fig. 1b). The highest number of birds
died between 74 and 83 days of age (Fig. 1c). Total mortal-
ity amounted to 37.1% while 29% of turkeys died within
10 days following onset of disease in the holding. Since
birds had been vaccinated twice and there was no recent
record of HPAIV H5N1 in that region, postmortem exam-
ination was conducted on the farm. Birds suffered severe
congestion of all internal organs including lungs. The pre-
liminary early diagnosis suggested a bacterial infection and
therefore antibiotics were used to treat the flock, but with-
out success. Emergency vaccination with live NDV vaccine
was also administered via drinking water at day 73 (Table 1)
due to the low anti-NDV HI titer (GMT= 24 - 25; data not
shown).
Laboratory diagnosis
Swab samples were inoculated into 9-day-old SPF ECE and
examined by HA/HI tests and RT-PCR. All embryonated
eggs died within 48 h post inoculation and HA test was
positive from allantoic fluid. Avian influenza virus was con-
firmed using HI test. Samples were submitted to the FLI for
further confirmation. The results of RT-qPCRs confirmed
the presence of H5N1 and revealed negative results for H7,
H9 and N2. The cross reactivity of TK16 was studied by HI
test using serum samples generated against different H5
viruses as shown in Table 2. HI titers produced by TK16
were 4 – 8 fold lower than these produced by the homolo-
gous viruses in clades 2.2.1.2, 2.2 and clade 1 and 32 fold
lower than those in clades 2.2.1.1 and 2.3.4.4 (Table 2). This
difference in antigenic drift was not correlated with the glo-
bal HA gene or protein identity ratios (Table 2).
Sequence analysis
Nucleotide and amino acid (aa) identities for each gene
were calculated by BioEdit and manually and summarized
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in Fig. 2, a list of mutations is supplied in Additional file 1:
Table S1.
Hemagglutinin (HA) gene
The HA of TK16 shared 95.1% aa identity with the
vaccine VacDK06 strain with 27 aa differences: one aa in
the signal peptide, 24 aa in the HA1 and 2 aa in the HA2.
These mutations are in residues 43, 61, 83, 120, 129, 140,
141, 151, 155, 156, 162, 174, 181, 189, 227, 235, 252, 263,
269, 272, 310, 322, 323, 325, and 328 in the HA1 subunit,
in addition to 373 and 473 in the HA2 subunit. Substitu-
tions in residues 155 and 156 resulted in the loss of a
potential glycosylation site in the head domain of TK16
(Fig. 3). The only available sequence of Mexican H5N2
virus is the HA1 which shared 83.5% aa and 78.4% nucleo-
tide identities with the current Tk2016. Compared to
Fig. 1 Performance (a) and number of dead birds of the meat-turkey flock in this study per week (b) or per day since the appearance of clinical signs (c)
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viruses from 2006, the mature HA possessed 46 nucleo-
tide differences, 14 out of them resulted in 11 aa changes,
whereas 32 were silent. The amino acid differences are in
positions 43, 120, 129, 151, 154, 155, 162, 272, 325, 373,
and 537 (Fig. 3). Compared to the recent viruses in clade
2.2.1.2 from human and poultry, there was no new amino
acid change but three non-synonymous mutations.
Neuraminidase (NA)
The NA of the virus shared 93.8% aa identity with the
vaccine strain with 28 aa substitutions in residues 20, 29,
34, 44, 46, 48, 50, 52, 53, 56, 58, 75, 80, 180, 204, 221,
228, 244, 250, 269, 284, 319, 326, 362, 366, 378, 409 and
430 (Fig. 3). The NA active and framework sites as well
as the hemadsorption sites are conserved. TK16
possesses markers sensitive to the neuraminidase inhibi-
tor Oseltamivir: V96, I97, E99, K130, D179, I203, Y233
and H255 (equivalent to N2 numbering residues 116,
117, 119, 150, 197, 222, 252 and 274, respectively). Com-
pared to viruses from 2006 there were 16 aa differences
in residues 20, 29, 34, 46, 48, 56, 74, 91, 180, 204, 221,
244, 284, 319, 378, and 430. Only 3 new mutations were
found: N180S, V221I and D378E. Additionally, muta-
tions in position 50–52 resulted in a potential GS which
was not present in the parent 2006-virus. Compared to
the recent viruses in clade 2.2.1.2b, they are only differ-
ent in position 46; the 2.2.1.2a possesses aspartic acid
while 2.2.1.2b possesses Asparagine in addition to one-
non-synonymous mutation.
Other gene segments
Identity matrices of all gene segments indicated that
TK16 has ≥98.8 nucleotide and aa similarity to recent
poultry and human isolates in Egypt, Israel and Gaza,
and up to 91% identity to the vaccine strain (Fig. 2).
Compared to the parental 2006-virus and variant 2.2.1.1
clade TK16 shared ≥96.7 and ≥95 nucleotide and ≥95.1
and ≥94.6 aa identities, respectively. Mutations in TK16
compared to other viruses in Egypt and the vaccine
strain are summarized in Additional file 1: Table S1.
Most of mutations were similar to previous reports [25–
27] except in PB2 (n = 7), PB1 (n = 1), PA (n = 11), NP
(n = 4), M1 (n = 1), M2 (n = 2) and NS1 (n = 9) as shown
Additional file 1: Table S1.
Phylogenetic analysis
Phylogenetic relatedness of all gene segments was deter-
mined by Bayesian inference analysis in MrBayes using
Table 1 Vaccination program of the flock
Vaccine Type Age of vaccination (Day) Route of Vaccination
NDV (Hitchner B1) + IB Live 6 Ocular
NDV + AI (H5N2; Mexico/94) Inactivated 8 Subcutaneous
Avian Metapneumovirus (TRT) Live 15 Ocular
NDV (Clone 30) Live 20 Ocular
HE Live 26 Drinking Water
AI (H5N1; Re-5) Inactivated 34 Subcutaneous
Poxvirus Live 40 Wing Web
P. multocida Inactivated 41 Subcutaneous
NDV (Clone 30) Live 50 Drinking Water
NDV (Lasota) Live 73 Drinking Water
ND = Newcastle Disease, IB=, Infectious Bronchitis, AI = Avian Influenza, TRT = Turkey rhinotracheitis, HE = Hemorrhagic Enteritis
H5N2 vaccine is seeded by A/chicken/Mexico/232/CPA/94(H5N2)
Re-5 vaccine strain carry the HA and NA genes of A/duck/Anhui/1/2006(H5N1)
Table 2 Antigenic characterisation of A/turkey/Egypt/AR1507/2016(H5N1) (TK16) isolated from vaccinated turkeys in this study
Serum samples against: Clade HI titer (log2) against HA identity*
TK16 Homologous antigen
A/chicken/Egypt/AR234-FAOF8NLQP/2014 (H5N1) 2.2.1.2 7 9 99.4/100
A/chicken/Egypt/0879-NLQP/2008 (H5N1) 2.2.1.1 5 10 94.7/94.2
A/teal/Germany/WV632/2005 (H5N1) 2.2 6 9 88.7/90.6
A/turkey/Germany-MV/R2472/2014 (H5N8) 2.3.4.4 2 7 88.7/90.6
A/Vietnam/1194/2004 (H5N1) 1 6 8 93.2/95.1
HA identity ratio was calculated for nucleotides and deduced amino acids after alignment of the gene sequence and deduced amino acids using Bio Edit by
the equation
100 - (Length of gene segment - Number of mutations/Length of gene segment)
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the best fit model predicted by jModelTest. Phylogenies
of all gene segments of TK16 showed similar topology.
In the HA, the recent viruses in clade 2.2.1.2 grouped in
three distinct subclade designated subclade A, B and C.
TK16 belonged to clade 2.2.1.2a clustering with gene se-
quences from recent viruses isolated in 2014 and 2015
in poultry in Egypt, Gaza and Israel (Fig. 4). This new
cluster is supported by a high posterior probability value
and possesses 3 unique non-synonymous mutations
compared to viruses in group 2.2.1.2b which were iso-
lated in the recent upsurge in 2014/2015. Likewise, the
NA was also very closely related to the available se-
quences of viruses isolated in poultry in Israel and Gaza
forming along with viruses from poultry in 2014/2015 in
Egypt a distinct cluster from human viruses in 2014/
2015. Similar topology was observed for the phylogenies
of other gene segments (Additional file 2 Figure S1).
Discussion
Vaccination of domestic poultry with H5 vaccines has
been implemented in several countries to limit the
spread of H5N1 AI virus. Many studies have shown that
vaccination of poultry with antigenically related vaccines
protected birds from morbidity, mortality and virus ex-
cretion [28–32]. However, insufficient efficacy of the
vaccines was reported after the infection with antigenic
drift variants [16, 18, 19]. A recent study has also shown
that H5N1 clade 7.2 viruses have not been eradicated
from poultry in China through intensive vaccination
[33]. In the contrast to chickens, less is known about
Fig. 2 Identity matrix of all gene segments of A/turkey/Egypt/AR1507/2016 to relevant H5N1 viruses. Nucleotide and amino acids identity matrices of all
proteins of A/turkey/Egypt/AR1507/2016 compared to related viruses of chicken and human origins, the ancestral 2006 virus, the variant 2.2.1.1 strain and
vaccine strain. TK16 =A/turkey/Egypt/AR1507/2016, IS-15 = A/turkey/Israel/633/2015 (clade 2.2.1.2), Human-14 =A/Egypt/MOH-NRC-7271/2014 (clade 2.2.1.2),
CK06 =A/chicken/Egypt/06553-NLQP/2006 (clade 2.2.1), CK14 =A/chicken/Egypt/A10351A/2014 (clade 2.2.1.2), CK09 =A/chicken/Egypt/096 L-NLQP/2009
(clade 2.2.1.1), and VacDk06 = vaccine strain A/duck/Anhui/1/2006 (clade 2.3.4); ID = identical, Identity of the nucleotides and amino acids was calculated by
the equation: 100 - (Length of gene segment - Number of mutations/Length of gene segment)
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HPAI H5N1 infection in vaccinated turkeys. In this
manuscript, we describe a vaccinal break in a meat-
turkey flock vaccinated twice with two different inacti-
vated H5 vaccines. Clinical signs and sudden onset of
mortality were reported few weeks after the last vaccin-
ation. Interestingly, 29% mortality within 10 days was
observed and surviving turkeys showed a transient drop
in feed consumption and body weight. In the available
literature no data are available on the efficacy of Re-5 to
protect turkeys against challenge with Egyptian H5N1-
like viruses. Re-5 was efficient to protect chickens from
mortality after experimental infection with early H5N1
viruses in clade 2.2.1 and 2.2.1.1, although virus shed-
ding was significantly higher than in birds vaccinated
with a local vaccine [34]. In an experiment, 20 to 100%
mortality during a 10 days observation period were de-
scribed in turkeys vaccinated with either H5N1 or H5N2
vaccines after challenge with Egyptian HPAIV H5N1 of
clade 2.2.1.1 [35].
In this study, data about the levels of anti-H5 anti-
bodies in serum samples from the infected turkey flock
are unfortunately missing. However, antigenic character-
isation indicated antigenic drift particularly against
serum samples from clade 2.2.1.1 in poultry in Egypt
and to lesser extent against serum samples from genetic-
ally related 2.2.1.2 virus (Table 2). Also, TK16 showed
remarkable antigenic drift against the recent H5N8
2.3.4.4 viruses, descendent clade from the vaccine strain.
Unlike 2.2.1.1 viruses which circulated in Egypt from
2007 to 2014, viruses in clade 2.2.1.2 showed less, if any,
antigenic variation, and vaccination of chickens was effi-
cient even with highly diverse H5 vaccines derived from
the Egyptian viruses [34, 36]. However, TK16 showed a
substantial genetic diversity at the protein level when
compared with VacDK06 (clade 2.3.4) especially in HA
and NA. In HA TK16 possessed up to 28 amino acids
different from VacDK06. In addition to the 2.2.1.2 clade-
specific signature (residues D43N, S120D, Δ129S I151T,
R162K, G272S, R325K) which enabled efficient replica-
tion of the Egyptian 2.2.1.2 viruses in human cells and
mice [24, 37, 38], several mutations in the immunogenic
epitopes (L71I, I83A, R140K, S141P, D155N, A156T,
V174I, P181S, T263A) [39] mostly in the HA1 head
domain (Fig. 3) were observed in the new 2.2.1.2a sub-
clade including TK2016. Some of these mutations are
shared with viruses in clade 2.2.1.1 (e.g. L71I, R140K,
S141P and A156T). These enabled the latter viruses to
escape from the humoral immune response induced by
H5 vaccines [40] and resulted in vaccination failure in
chickens [34]. In the NA, unlike 2.2.1.1 clade viruses
which contain only a single amino acid change com-
pared to the viruses in 2006 and few mutations com-
pared to the vaccine strains [41], clade 2.2.1.2 viruses
including TK16 possess several substitutions in the NA.
Residue A20, I29, I34, S44, A46, S48, S50, T52, K53,
A56, and K58 are located in the stalk region [42] while
the others are positioned at the head domain of the NA
monomer (Fig. 3). Some amino acid changes are in the
NA immunogenic epitope A (362, 366 equivalent to N2
numbering 385, 389), epitope B (180 equivalent to N2
Fig. 3 Predicted location of amino acids in the HA and NA proteins of A/turkey/Egypt/AR1507/2016(H5N1). Shown are mutations in HA (a) and NA (b) in
TK16 compared to the vaccine strain Dk2006. (a) Most of mutations in the HA occurred in the head domain (transparent grey circle): mutations in the
immunogenic epitopes (red), receptor binding sites (blue), de-glycosylated sites (green), in the proteolytic cleavage site (yellow) and those with unknown
function (cyan). (b) in the NA, mutations occurred in the stalk (n= 11; while residues 20, 29, 34, 44 and 46 are not shown in the 3D structure) and head
domain (n= 17), the sialidase functional and framework sites (magenta), mutations in the immunogenic epitopes (red), glycosylated sites (green), and those
with unknown function (cyan) are shown. All mutations are imposed on the HA and NA of the parent A/chicken/Egypt/NLQP-06207/2006 virus
Salaheldin et al. Virology Journal  (2017) 14:48 Page 6 of 11
199) or epitope C (residue 319 equivalent to 339 N2
numbering) [43]. Meanwhile, 378 (equivalent to 402 N2
numbering) is located close to immunogenic epitope A,
204 (N2 numbering 223) close to epitope B and between
two framework and functional residues of the sialidase,
and 326 (equivalent to 349 N2 numbering) is close to
epitope C [43]. Together, continuous circulation of clade
2.2.1.2 viruses in vaccinated poultry resulted in the
emergence of another antigenic variant sub-clade dis-
tinct from the human viruses in clade 2.2.1.2 resembling
the situation in 2006 when the parental clade 2.2.1
diverged into two distinct clades: 2.2.1.1 in poultry in
2007–2014 and 2.2.1.2 in non-vaccinated poultry and
humans in 2008–2016.
The source of infection in this flock is not yet clear.
There was no infection in adjacent layers-flock premises
according to the official reports. Since the turkey flock
was vaccinated against NDV several days before starting
the increased mortality the vaccination crew may be
responsible for the introduction of the virus. This
remains speculative, however. Moreover, phylogenetic
analysis indicated a very close relationship of TK16 with
recent viruses from Israel and Gaza in 2015. Since the
flock was kept in an open system house, transmission by
feral birds (e.g. pigeons, sparrows or egrets) or migratory
birds (e.g. waterfowl) can not be excluded. Legal poultry
trade between Egypt and both regions is not known and
smuggling of poultry or feed is unlikely.
Conclusions
Our study is important because so far no data on the in-
fection of vaccinated turkeys with HPAI H5N1 virus
under field conditions are available. Likewise, data are
scarce about performance (e.g. feed consumption and
body weight) of turkeys during the course of HPAI
H5N1 infection. Antigenic characterisation indicated
genetic drift. Full genome analysis along with other vi-
ruses from Egypt, Israel and Gaza indicated the emer-
gence of a new cluster supported by high posterior
probability and therefore designated clade 2.2.1.2a.
Fig. 4 Phylogenetic analysis of the HA (a) and NA (b) gene segments of A/turkey/Egypt/AR1507/2016 to other related H5N1 viruses in poultry
and humans. Phylogenetic analysis of the HA (a) and NA (b) genes of Egyptian viruses showing different genetic clades. Viruses in 2015 from
Egypt, Gaza and Israel are clustered in clade 2.2.1.2 in three distinct subclades denoted A, B and C. A/turkey/Egypt/AR1507/2016 is located in
subclade A along with recent viruses isolated in 2014 and 2015 in poultry in Egypt, Gaza and Israel. Subclade B represents viruses of human and
poultry origin in 2014/2015, and subclade C contains viruses from poultry origin in Egypt in 2015
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Further research is required to evaluate the efficiency of
current vaccines to protect turkeys against infection with
the new viruses. Also, mutations demonstrated here with
unknown biological functions should be further investi-
gated. The new cluster carries signatures from both
chicken-adapted and human-adapted clades which war-
rants vigilance to prevent at an early stage the spread of
human-adapted strains in Egypt.
Methodology
Flock history
The affected population was a meat-turkey flock con-
taining 2040 male BUT-Big6 turkeys. They were
reared in an open system house with good hygienic
conditions. At a distance of about three-hundred
meters a layer chicken farm was located. The feed was
manufactured in the company feed mill supplemented
by anticoccidials, anti-microbial growth promotors
and antimycotoxins; all ingredients were used accord-
ing to the species requirement. Water supply was from
an underground source. Birds were vaccinated sub-
cutaneously at 8 day-of age with a bivalent vaccine
containing A/chicken/Mexico/CPA/1994(H5N2) and
Newcastle disease virus (NDV), and boostered for AI
at 34 days old using Re-5 vaccine containing HA and
NA from A/duck/Anhui/1/2006(H5N1) clade 2.3.4
(designated VacDK06) and other gene segments from
A/Puerto Rico/1/1934(H1N1). Additionally, the flock
was revaccinated and/or vaccinated against NDV,
Avian Metapneumovirus (Turkey rhinotracheitis-
TRT), Hemorrhagic enteritis, poxvirus, and Pasteur-
ella multocida (Table 1).
Sample collection
Cloacal and oropharyngeal swabs were collected from
25 birds at the onset of the clinical signs, or from dead
birds. Swabs were placed in transport medium, con-
sisting of phosphate-buffered saline containing gly-
cerol, penicillin (2000 U/ml), gentamicin (250 mg/ml)
and nystatin (500 U/ml). Collected swab samples were
sent to the Faculty of Veterinary Medicine, Damanhur
University, Egypt for routine diagnosis. Samples were
also sent to the OIE and National Reference Labora-
tory for Avian Influenza, Federal Research Institute for
Animal Health, Friedrich-Loeffler-Institut, Germany
for further virus characterization. In this study, no
experimental research was conducted and all turkeys
were handled according to the standard guidelines.
Virus isolation
Virus isolation from swab samples was done in 9-day-
old specific-pathogen-free (SPF) embryonated chicken
eggs (ECE) according to the OIE guidelines [44].
Inoculated eggs were examined daily for 3 – 5 days. Eggs
with dead embryos were kept at 4 °C for 24 h. Allantoic
fluid was collected and examined using the standard
hemagglutination test and 1% chicken erythrocytes.
Allantoic fluids of positive eggs were pooled together
and tested by the hemagglutination inhibition (HI) test
for the presence of H5 and ND viruses using specific
antisera [44].
Antigenic characterisation
Sera against different H5 viruses as well as homologous
antigens were obtained from the repository of the FLI.
Cross-reactivity of TK16 against different sera was stud-
ied by hemagglutination inhibition (HI) test. The HI test
was done against 1% chicken erythrocytes and 4 HA
units of each antigen in 96-well plastic V-bottomed
microtiter plates according to the OIE manual [44]. The
test was done in duplicates and the titers produced
against TK16 were compared to those produced by the
homologous antigens.
Real-time reverse-transcription polymerase chain reaction
(RT-qPCR)
Viral RNA was extracted from swab media using the
QIAamp Viral RNA Kit (Qiagen, Hilden, Germany) fol-
lowing the manufacturer’s instructions. RT-qPCR
specific for the AIV M gene was followed by RT-qPCRs
specific for the HA of H5, H7, H9 HA-subtypes and N1
and N2 NA-subtypes using primers published by Hoff-
mann et al. [45].
Sequencing and sequence analysis
Complementary cDNA was generated from 4 μl RNA
using Omniscript RT Kit (Qiagen, Hilden, Germany)
along with a primer specific to the conserved 12 nucleo-
tide of 3’end of the viral RNA as previously published
[46]. The HA, NP, NA, M and NS gene segments were
amplified using universal primers and 1 μl of cDNA
according to Kreibich et al. [47], whereas the PB2, PB1
and PA genes were amplified using internal primers to
generate long overlapping regions (primers are available
upon request). All PCR reactions were performed in
Thermocycler machine (Eppendorf, Hamburg, Germany)
as previously done [47]: an initial denaturation step (98 °
C 30 s), followed by 35 cycles each consisting of 98 °C
10s, 60 °C 30s, 72 °C 6 min and final elongation (72 °C
5 min) utilizing 2 U Phusion High-Fidelity DNA Poly-
merase (New England BioLabs, Frankfurt am Main,
Germany) according to the manufacturer’s guidelines.
Fragments’ sizes were determined by electrophoresis in
1% agar gel in comparison to the GeneRuler™ DNA
ladder (Thermo Scientific, Germany). Amplicons were
excised and purified using the QIAquick Gel Extraction
Kit (Qiagen, Hilden, Germany). The purified PCR
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products were sequenced using a BigDye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems,
Langen, Germany) and appropriate primers purified
with NucleoSEQ® Columns (MACHEREY-NAGEL
GmbH & Co. KG). Sanger sequencing was conducted in a
3130 Genetic Analyzer (Applied Biosystems). Sequences
of full genome of the virus isolated in this study were
submitted to the Global Initiative on Sharing All Influenza
Data (GISAID) and assigned accession numbers: EPI827065
to EPI827072. N-linked glycosylation in the HA and NA
proteins were predicted by NetNGlyc 1.0 Server. The loca-
tion of mutations described in the HA and NA in this study
was predicted on the tertiary structure of the corresponding
proteins of the parent 2.2.1 virus (A/chicken/Egypt/NLQP-
06702/2006) using SWISS MODEL (http://swissmodel.e
xpasy.org/) and then viewed and edited by geneious soft-
ware suite v.8.1.3 (Biomatters, Auckland, New Zealand).
Phylogenetic analysis
Sequence similarity to each gene segment of the virus
isolated in this study was detected by Basic Local Align-
ment Search Tool (BLAST) database available at the
NCBI [48]. Sequences with the maximum BLAST
scores and identity percentages were selected. More-
over, all viruses in 2014–2015 from Egypt, Israel and
Gaza as well as representative viruses from clades 2.2.1
and 2.2.1.1 were downloaded. All sequences were
aligned by Multiple Alignment using Fast Fourier
Transform (MAFFT) [49] and further viewed and edi-
ted by BioEdit 7.1.7 [50]. Amino acid sequences were
deduced from gene sequences and identity matrices
were calculated using BioEdit and manually. Bayesian
inference phylogenetic trees for each gene segment
were generated using MrBayes 3.2.6 [51] under best-fit
models calculated by jModelTest [52]. Two parallel
runs consisted of four chains of Markov Chain Monte
Carlo (MCMC) iterations for 108 generations were se-
lected for each nucleotide sequence. For each phylogen-
etic tree A/goose/Guangdong/1/1996(H5N1) (Clade 0)
was specified as the out-group. Graphic outputs were
produced by FigTree (http://tree.bio.ed.ac.uk/software/
figtree/) and Inkscape 0.91 (www.inkscape.org).
Additional files
Additional file 1: Table S1. Amino acids differences from A/turkey/
Egypt/AR1507/2016 and ancestral 2006 virus, vaccine strain and closest
human isolate (DOC 36 kb)
Additional file 2: Figure S1. Phylogenetic analysis of internal protein
coding gene segments of A/turkey/Egypt/AR1507/2016 to other related
H5N1 viruses in poultry and humans. Phylogenetic analysis of non HA/NA
genes of Egyptian viruses showing different genetic clades. Viruses in
2015 from Egypt including A/turkey/Egypt/AR1507/2016 are clustered in
clade 2.2.1.2. The tree was generated by MrBayes under the best-fit
model selected by jModelTest. (PDF 701 kb)
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